Østerrike - tysk - AGES (Agentur für Gesundheit und Ernährungssicherheit)

hexal pharma gmbh - atorvastatin calcium -

Nigeria - engelsk - NAFDAC (National Agency for Food and Drugs Administration and Control)

dafra pharma gmbh - film coated tablets - amoxicillin 875mg, clavulanic acid 125mg - dafraclav® is indicated in the treatment of the following infections caused by the microorganisms indicated below. upper respiratory tract infections (including otitis media and sinusitis) due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. lower respiratory tract infections due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. skin and skin structure infections due to beta-lactamase producing strains of staphylococcus aureus, escherichia coli and klebsiella spp. urinary tract infections. since dafraclav® contains amoxicillin, it can be used in the treatment of infections caused by bacteria susceptible to ampicillin. additionally, if in a mixed infection a microorganisms is susceptible to ampicillin and the other which is a beta-lactamase producer is susceptible to dafraclav®, such an infection can be treated by the administration of dafraclav® alone, addition of another antibiotic is not required.

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

aristo pharma gmbh (3082323) - buprenorphin - transdermales pflaster - 15 mikrogamm/stunde - teil 1 - transdermales pflaster; buprenorphin (20180) 15 milligramm

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

aristo pharma gmbh (3082323) - buprenorphin - transdermales pflaster - 25 mikrogamm/stunde - teil 1 - transdermales pflaster; buprenorphin (20180) 25 milligramm

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

aristo pharma gmbh (3082323) - buprenorphin - transdermales pflaster - 30 mikrogamm/stunde - teil 1 - transdermales pflaster; buprenorphin (20180) 30 milligramm

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

aristo pharma gmbh (3082323) - buprenorphin - transdermales pflaster - 40 mikrogamm/stunde - teil 1 - transdermales pflaster; buprenorphin (20180) 40 milligramm

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

eureco-pharma b.v. - fluvoxaminewaterstofmaleaat samenstelling overeenkomend met; fluvoxamine; - filmomhulde tablet - fluvoxamine

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

eureco-pharma b.v. - fluvoxaminewaterstofmaleaat samenstelling overeenkomend met; fluvoxamine; - filmomhulde tablet - fluvoxamine

Nigeria - engelsk - NAFDAC (National Agency for Food and Drugs Administration and Control)

dafra pharma gmbh - amoxicillin 200mg,clavulanic acid 28mg - dafraclav® is indicated in the treatment of the following in­fections caused by the microorganisms indicated below. upper respiratory tract infections (including otitis media and sinusitis), due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. lower respiratory tract infections, due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. skin and skin structure infections, due to beta-lactamase producing strains of staphylococcus aureus, escherichia coli and klebsiella spp. urinary tract infections. since dafraclav® contains amoxicillin, it can be used in the treatment of infections caused by bacteria susceptible to ampicillin. additionally, if in a mixed infection a microorganisms is susceptible to ampicillin and the other which is a beta-lactamase producer is susceptible to dafraclav®, such an infection can be treated by the administration of dafraclav® alone, addition of another antibiotic is not required.

Den europeiske union - engelsk - EMA (European Medicines Agency)

merz pharmaceuticals gmbh - memantine hydrochloride - alzheimer disease - other anti-dementia drugs - treatment of patients with moderate to severe alzheimer's disease.